The Inhibitory Effect of Aspirin on Platelet and Vascular Prostaglandins in Rats cannot be Completely Dissociated
Authors:
- Giovanni de GaetanoGGGiovanni de Gaetano
- 1 July 1979
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 42 (3) , 425-431
Abstract
Summary. Blood platelets and vascular endothelium generate prostaglandin derivatives with opposing effects: cyclic endoperoxides and thromboxane A2 (TXA2) aggregate platelets, whereas prostaglandin I2 (PGI2, prostacyclin) inhibits aggregation. Since aspirin inhibits the synthesis and effects of all these metabolites of arachidonic acid, the rationale for clinical use of this drug in thrombosis prevention trials is questionable. Treatment schedules would have to be calibrated to inhibit proaggregating platelet prostaglandins and TXA2 without affecting protective vascular prostaglandins (PGI2). This important clinical information cannot easily be obtained from studies in man.The present study indicates that normal rat platelets are more sensitive to aspirin (ID50=3.6 mg/kg) than arterial tissues (ID50=25.0 mg/kg) and are almost as sensitive as venous tissues (ID50=2.3 mg/kg). Platelet prostaglandin production was monitored through the measurement of malondialdehyde (MDA) output under standard stimulation with thrombin. PGI2‐like activity released from the abdominal aorta and inferior vena cava was determined as platelet aggregation inhibitory potency and characterized by standard criteria.The inhibitory effect of aspirin (at doses of 10 and 50 mg/kg) on platelet MDA production lasted much longer in platelets (96–120 h) than in venous (24–72 h) or arterial tissue (less than 24 h). The findings suggest that in rats the (potentially antithrombotic) effect of aspirin on platelet prostaglandin and TXA2 generation may be distinguished, though not completely, from the (potentially prothrombotic) effect on vascular PGI2 on the basis of duration of inhibition more than on the sensitivity of the target cells to the drug. The different capacities of anucleated platelets and of nucleated vascular endothelial cells to overcome aspirin inhibition could be exploited for more rational clinical use of this drug.Keywords
This publication has 22 references indexed in Scilit:
- DIPYRIDAMOLE AND OTHER PHOSPHODIESTERASE INHIBITORS ACT AS ANTITHROMBOTIC AGENTS BY POTENTIATING ENDOGENOUS PROSTACYCLINThe Lancet, 1978
- Inhibition of platelet prostaglandin synthetase by oral aspirin.Journal of Clinical Investigation, 1978
- Aspirin and Thromboembolism — A Possible DilemmaNew England Journal of Medicine, 1977
- PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILUREThe Lancet, 1977
- Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandinBiochemical and Biophysical Research Communications, 1977
- PROSTACYCLIN AND ATHEROSCLEROSIS IN RATSThe Lancet, 1977
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Metabolism of [14C]arachidonic acid by human plateletsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1976
- An Enzymatic Mechanism for the Antithrombotic and Antihemostatic Actions of AspirinScience, 1974